In the New Era of ASCVD Lipid Risk Management: You Manage the Case
The therapeutic landscape for ASCVD is evolving rapidly. Stay ahead of the clinical curve with this interactive case-based broadcast featuring renowned cardiovascular experts sharing the latest evidence-based standards of practice in ASCVD risk reduction and treatment.
This engaging virtual program features 4 nationally recognized experts in the management of ASCVD risk assessment and treatment, sharing exciting updates on emerging therapeutic options stemming from late-breaking clinical trials. Case-based learning models will simulate and apply key concepts into clinical practice.
Once registered, please be on the lookout for a confirmation email with testing instructions.
1:00 pm–1:10 pm | Welcome, Introductions, Program Overview, and Pre-Activity Test Questions |
1:10 pm–1:30 pm | Update on Determining Risk Status in ASCVD |
1:30 pm–1:50 pm | New Approaches to the Management of Patients at High-Risk of CVD Events |
1:50 pm–2:15 pm | Managing ASCVD Risk Beyond LDL-C Lowering Therapy |
2:15 pm–2:35 pm | Practical Considerations to Manage Residual Risk |
2:35 pm–2:55 pm | Discussion and Question & Answers |
2:55 pm–3:00 pm | Closing Comments, and Adjourn |
At the conclusion of this activity, learners should be better able to:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and Medtelligence. GLC is accredited by the ACCME to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This course is designed to meet the continuing medical education needs of the Internal Medicine and Primary Care Physicians and allied health professionals who treat patients with, or at high risk of, ASCVD.
This activity is supported by an independent educational grant from Amarin Pharma, Inc.
For all devices:
Please note that the Logitech C920 and C930 models are NOT supported by Pando.
If you have one of these Logitech webcams, please plan to replace prior to the meeting
Windows PC:
| Macintosh:
| iPad:
|
This engaging virtual program features 4 nationally recognized experts in the management of ASCVD risk assessment and treatment, sharing exciting updates on emerging therapeutic options stemming from late-breaking clinical trials. Case-based learning models will simulate and apply key concepts into clinical practice.
Once registered, please be on the lookout for a confirmation email with testing instructions.
1:00 pm–1:10 pm | Welcome, Introductions, Program Overview, and Pre-Activity Test Questions |
1:10 pm–1:30 pm | Update on Determining Risk Status in ASCVD |
1:30 pm–1:50 pm | New Approaches to the Management of Patients at High-Risk of CVD Events |
1:50 pm–2:15 pm | Managing ASCVD Risk Beyond LDL-C Lowering Therapy |
2:15 pm–2:35 pm | Practical Considerations to Manage Residual Risk |
2:35 pm–2:55 pm | Discussion and Question & Answers |
2:55 pm–3:00 pm | Closing Comments, and Adjourn |
At the conclusion of this activity, learners should be better able to:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and Medtelligence. GLC is accredited by the ACCME to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This course is designed to meet the continuing medical education needs of the Internal Medicine and Primary Care Physicians and allied health professionals who treat patients with, or at high risk of, ASCVD.
This activity is supported by an independent educational grant from Amarin Pharma, Inc.
For all devices:
Please note that the Logitech C920 and C930 models are NOT supported by Pando.
If you have one of these Logitech webcams, please plan to replace prior to the meeting
Windows PC:
| Macintosh:
| iPad:
|
Facebook Comments